IDH1 Mutant Glioma Xenograft (JHH-273) mouse

This model meets a critical need to test drug agents targeting mechanisms involved in glial tumor formation.

Contributors

Inventor Institute
Gregory Riggins Johns Hopkins University
SKU: 156429
Product description: An in vivo Isocitrate Dehydrogenase (IDH-1) glioma mouse xenograft model has been developed to further study effective therapies for IDH mutations characterized by increased DNA methylation and production of the common oncometabolite, 2-HG. Difficult grafting cell-culture techniques and current engineered cell line quality have limited additional laboratory studies; however, this model was developed directly from a WHO grade III- glial cell positive cancer patient tissue (JHH273) with a confirmed IDH mutation through DNA sequencing and maintains IDH-1 mutation features observed in human primary glial brain tumors. Additionally, when models were exposed to a demethlyating agent, 5-azacytidine, a reduction in methylation and tumor growth was observed opening the door for more clinical analysis. This model meets a critical need to test drug agents targeting mechanisms involved in glial tumor formation.
Genetic background: 4–6-week old female athymic nude mice
Cat. #: 156429
Research Fields: Cancer; Drug development
Target: IDH1
Disease: Glial tumor formation
Model: Mutant
Phenotype: 4–6-week old female athymic nude mice
Shipping conditions: Embryo/Spermatoza- Dry Ice
References:

Borodovsky et al. 2013. Oncotarget. 4(10):1737-47. PMID: 24077805.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.